Experts urge more representative enrollment in clinical trials

A panel of regulators and industry leaders gathered to discuss how clinical trials can better reflect the diversity of patient populations. The discussion included officials from the U.S. Food and Drug Administration, the European Medicines Agency, and various industry representatives.

The speakers offered practical advice on designing studies that recruit participants across different ages, genders, ethnicities, and disease sub‑types. They emphasized that broader enrollment can improve the relevance of trial results and support more inclusive drug development.

Attendees were reminded that achieving representative enrollment is a shared responsibility among sponsors, investigators, and regulatory bodies, and that ongoing collaboration will be key to implementing these recommendations.